ISRCTN14819975 https://doi.org/10.1186/ISRCTN14819975

Deferred registration: Quotient Sciences Code: QSC304473

Submission date 30/07/2026	**Recruitment status** Not yet recruiting	[X] Prospectively registered [_] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [X] Record updated in last year
Registration date 14/08/2026	**Overall study status** Deferred	
Last Edited 14/08/2026	**Condition category** Other	

Plain English summary of protocol
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Contact information

Type(s)
Principal investigator

Contact name
Dr Philip Evans

Contact details
Mere Way
Ruddington Fields
Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 (0)3303031000
recruitment@weneedyou.co.uk

Type(s)
Public, Scientific

Contact name
None Global Clinical Operations

Contact details
611 Gateway Boulevard
Suite 900
South San Francisco

San Francisco
United States of America
CA 94080 USA
+1 650 624 1100
clinicaltrials@rigel.com

Additional identifiers

Integrated Research Application System (IRAS)
1014407

CRO Study Code
Quotient Sciences Code: QSC304473

Study information

Scientific Title
Quotient Sciences Code: QSC304473 [Full scientific title to be added on or before the deferral expiry date]

Study objectives
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Ethics approval required
Ethics approval required

Ethics approval(s)
Submitted 30/06/2026, Wales Research Ethics Committee (REC) 2 (Health and Care Research Wales, Castlebridge 5, 15-19 Cowbridge Road East, Cardiff, CF11 9AB, United Kingdom; +44(0) 2920 785738; Wales.REC2@wales.nhs.uk), ref: 26/WA/0178

Primary study design
Interventional

Allocation
N/A: single arm study

Masking
Open (masking not used)

Control
Uncontrolled

Assignment
Single

Purpose
Phase I trial in healthy volunteers

Study type(s)

Health condition(s) or problem(s) studied
Healthy volunteers

Interventions
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Intervention Type
Drug

Phase
Phase I

Drug/device/biological/vaccine name(s)
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Primary outcome(s)
1. [Outcome name] measured using [Metric or method of measurement] at [Timepoint(s)]. This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Key secondary outcome(s)

Completion date
02/10/2026

Eligibility

Key inclusion criteria
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Healthy volunteers allowed
Yes

Age group
Mixed

Lower age limit
30 Years

Upper age limit
65 Years

Sex
Male

Total final enrolment
0

Key exclusion criteria
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Date of first enrolment
25/08/2026

Date of final enrolment
02/10/2026

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Quotient Sciences Limited
Mere Way
Ruddington Fields
Ruddington
Nottingham
England
NG11 6JS

Sponsor information

Organisation
Rigel Pharmaceuticals, Inc.

Funder(s)

Funder type

Funder Name
Rigel Pharmaceuticals, Inc.

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not expected to be made available